• Team
  • Portfolio
  • Careers
  • Blog
  • Subscribe
  • Twitter Twitter
  • Contact Us

© 2019 Two Sigma Investments, LP. All rights reserved

Two Sigma is proud to be an equal opportunity workplace. We do not discriminate based upon race, religion, color, national origin, sex, sexual orientation, gender identity/expression, age, status as a protected veteran, status as an individual with a disability, or any other applicable legally protected characteristics.

Two Sigma and the Two Sigma logo are trademarks of Two Sigma Investments, LP. Beaker® is a registered trademark of Two Sigma Open Source, LLC.

The portfolio companies shown represent substantially all of Two Sigma Ventures’ investment in companies as of September 20, 2019. Certain portfolio companies have been excluded in which Two Sigma no longer holds an interest and the company or product no longer exists. It should not be assumed that the investment in the portfolio companies identified was or will be profitable. For a full list of Two Sigma Ventures investments, please click here. Excluded from this list are investments for which the issuer has not provided permission for Two Sigma Ventures to disclose publicly.

This website is intended solely to provide general information about Two Sigma Ventures, its services to entrepreneurs, and its people. This website is not an offer to, or solicitation of, any potential clients or investors for the provision by Two Sigma of investment management, advisory or any other related services. No material listed on this website is or should be construed as investment advice, nor is anything on this website an offer to sell, or a solicitation of an offer to buy, any security or other instrument. Links from this website to third-party websites do not imply any endorsement by the third party of this website or of the link; nor do they imply any endorsement by this firm of the third-party website or of the link.

  • Legal Disclosure
  • Privacy Policy

Kallyope

Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. Their cross-disciplinary team integrates cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics to improve human health. The company’s founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D.

kallyope.com